Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has had stable moderate to severe plaque psoriasis for at least 6 months~* Subject has involved BSA ≥ 10% and PASI ≥ 10 at screening and at baseline.~* Subject is a candidate for systemic therapy or phototherapy in the opinion of the investigator~Exclusion Criteria:~* Subject has active guttate, erythrodermic, or pustular psoriasis at the time of the screening visit.~* Subject has evidence of skin conditions at the time of the screening visit (eg, eczema) that would interfere with evaluations of the effect of etanercept and/orclobetasol propionate foam on psoriasis.~* Subject diagnosed with medication-induced or medication exacerbated psoriasis~* Subject has any active Common Toxicity Criteria (CTC) grade 2 or higher infection~* Subject has a significant concurrent medical condition or laboratory abnormalities as defined in the study protocol.~* Subject has used any of the following therapies within 14 days of the first dose: UVB therapy or topical psoriasis therapies other than Class I or II topical steroids.~* Subject has used any of the following therapies within 28 days of the first dose: Class I or II topical steriods, UVA therapy (with or without psoralen), or systemic psoriasis therapies~* Subject has used one or more biologic therapies (other than interleukin (IL)12/IL23 inhibitors) within 3 months of the first dose~* Subject has used an IL-12/IL-23 inhibitor within 6 months of the first dose of etanercept~* Subject has ever used efalizumab (Raptiva®).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- etanercept and clobetasol (Type: EXPERIMENTAL): Etanercept 50 mg twice weekly x 12 weeks + clobetasol propionate foam (weeks 11 and 12) then Etanercept 50 mg once weekly x 12 weeks + clobetasol propionate foam (weeks 23 and 24)
- etanercept (Type: EXPERIMENTAL): Etanercept 50 mg twice weekly x 12 weeks then Etanercept 50 mg once weekly x 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).